시장보고서
상품코드
2130865

GI 변 검사 시장 분석 및 예측(-2035년) : 유형, 제품, 서비스, 기술, 용도, 프로세스, 최종사용자, 방법

GI Stool Testing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Mode

발행일: | 리서치사: 구분자 Global Insight Services | 페이지 정보: 영문 350 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 4,750 금액 안내 화살표 ₩ 6,505,000
PDF & Excel (Site License) help
PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.
US $ 5,750 금액 안내 화살표 ₩ 7,875,000
PDF & Excel (Enterprise License) help
PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 6,750 금액 안내 화살표 ₩ 9,244,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 GI 변 검사 시장은 2025년 3억 7,740만 달러에서 2035년까지 7억 6,340만 달러로, CAGR 7.3%로 확대할 것으로 예측됩니다. GI 대변 검사 시장은 소화기 감염증의 정확한 검출 필요성, 분자 진단법의 이용 확대, 그리고 세균, 바이러스, 기생충 등의 병원체에 대한 신속한 동정 수요에 의해 주도되고 있습니다. 2026년 2월, CDC는 스트롱길로이드증 진단에 있으며, 지속적인 대변 검사가 여전히 골드 스탠다드라는 견해를 밝히며, 대변 검사의 임상적 중요성이 여전히 높음을 강조했습니다. 또한 2025년 4월 CDC 지침에서는 알·기생충 검사법 및 항원 검사법을 포함한 기생충 질환에 대한 대변 검사의 중요성이 강조되었습니다. 다중 PCR, 항원 검출 및 자동화된 검사 분석 기술의 발전으로 진단 속도와 병원체 동정 정확도가 향상되고 있습니다.

위장관(GI) 대변 검사 시장 유형별 세분화에는 면역 분석법, 분자 검사, 크로마토그래피, 배양법 기반 검사, 현미경 검사 및 기타가 포함됩니다. 2025년에는 면역 분석법이 시장을 주도했습니다. 이는 광범위한 활용, 높은 비용 효율성, 신속한 결과, 그리고 소화기 감염증 및 바이오마커 검출 분야에서 확립된 응용 실적이 그 원인으로 꼽힙니다. 분자 검사는 PCR 기반 검사의 채택 확대, 민감도와 특이도의 향상, 병원체의 다중 검출, 그리고 신속하고 정확한 진단에 대한 수요 증가에 힘입어 예측 기간 중 가장 빠르게 성장하는 부문이 될 것으로 예상됩니다. 배양 검사와 현미경 검사는 여전히 기존의 진단 워크플로우를 지원하고 있지만, 크로마토그래피 및 기타 첨단 기술은 전문적인 대변 분석 및 바이오마커 검출 분야에서 주목을 받고 있습니다.

GI 대변 검사 시장의 최종사용자 부문에는 병원, 진단 검사 기관, 연구소, 재택 간호, 기타가 포함됩니다. 2025년에는 환자 수의 증가, 확립된 진단 인프라, 그리고 소화기 감염증 및 질환 진단에 대한 수요 증가로 인해 병원이 시장을 주도했습니다. 재택 간호는 편의성이 높은 검사, 자택에서의 검체 채취, 원격의료 서비스에 대한 수요 증가, 그리고 소화기 건강 모니터링에 대한 소비자의 관심 증가에 힘입어 예측 기간 중 가장 빠르게 성장하는 부문이 될 것으로 예상됩니다. 진단 검사 기관은 전문적인 검사 역량과 아웃소싱 추세로 인해 계속해서 중요한 역할을 수행하고 있는 반면, 연구소는 소화기 질환 연구 및 마이크로바이옴 연구에서 대변 검사의 활용을 확대하고 있습니다.

지역별 개요

2025년, 북미는 위장관(GI) 대변 검사 시장에서 가장 큰 지역이 되었습니다. 이는 첨단인 의료 인프라, 확립된 임상 검사실 네트워크, 높은 의료비 지출, 그리고 분자 진단 기술 및 면역 분석법에 기반한 진단 기술의 광범위한 도입에 힘입은 결과입니다. 이 지역은 확립된 대장암 검진 프로그램, 소화기 질환에 대한 높은 인식, 진단 서비스에 대한 원활한 접근성, 그리고 비침습적 대변 검사의 활용 확대라는 이점을 누리고 있습니다. 미국은 광범위한 의료 보험 적용 범위와 첨단 진단 시설의 존재에 힘입어 지역 수요의 주요 견인차 역할을 했습니다.

아시아태평양은 의료 인프라 확충, 의료비 증가, 소화기 질환에 대한 의식의 향상, 그리고 첨단 진단 기술의 보급에 힘입어 예측 기간 중 위장관(GI) 대변 검사 시장에서 가장 빠른 성장을 이룰 것으로 예상됩니다. 중국, 인도, 일본, 한국 등의 국가에서는 진단 서비스에 대한 접근성이 개선되고, 조기 및 정확한 질환 검출에 대한 수요가 증가함에 따라 지역 시장 확대에 크게 기여할 것으로 예상됩니다. 위장 감염증 및 기타 소화기 질환의 유병률 상승에 더해, 의료 시스템 및 진단 역량 강화를 위한 정부의 노력도 맞물려 이 지역 전체에서 대변 검사의 도입이 더욱 가속화될 것으로 예상됩니다.

주요 동향 및 촉진요인

다중 분자 검사 및 마이크로바이옴 기반 대변 검사로의 전환:

위장관(GI) 대변 검사 시장은 기존의 배양, 현미경 검사, 단일 분석물 분석에서 다중 PCR, 증후군별 분자 패널 및 미생물군집 프로파일링으로 점점 더 전환되고 있습니다. 다중 PCR 플랫폼은 단일 대변 검체에서 세균, 바이러스, 기생충 등 병원체를 동시에 식별할 수 있으며, 검사 소요 시간을 단축하고, 보다 정밀한 치료를 가능하게 합니다. 동시에 차세대 염기서열 분석 기술을 통해 대변 분석의 범위는 병원체 검출에 그치지 않고, 장내 미생물군집 및 장내 플로라의 불균형에 대한 특성 평가로 확대되어, 개인 맞춤형 소화기 의료를 지원하고 있습니다. 이러한 추세는 특히 급성 감염성 설사나 복잡한 위장 증상을 보이는 환자를 대상으로 한 신속한 증후군별 검사에 대한 임상적 관심이 높아짐에 따라 더욱 가속화되고 있습니다.

소화기 질환 및 대장암의 비침습적 검출에 대한 수요 증가:

GI 대변 검사 시장의 주요 촉진요인 중 하나는 대장암 검진, 염증성 장 질환 및 소화기 감염증에 대한 비침습적 대변 기반 진단법의 활용 확대입니다. FIT(분변 헤모글로빈 검사) 및 기타 분변 잠혈 검사는 대장 이상에 따른 소화관 출혈을 검출하기 위한 접근성이 높은 선별 수단을 제공하는 한편, 분변 칼프로텍틴 및 락토페린은 염증성 장 질환과 기능성 질환을 구별하는 데 도움이 되어 불필요한 침습적 검사를 줄일 수 있습니다. 대장암 검진 프로그램의 확대, 소화기 질환 발생률의 증가, 그리고 조기 발견의 필요성으로 인해 검사 건수는 증가하고 있습니다. 동시에, 다중 분자 검사법을 통해 급성 위장염의 병원체를 신속하게 동정하려는 수요가 높아지고 있습니다.

목차

제1장 개요

제2장 시장 하이라이트

제3장 시장 역학

제4장 부문 분석

제5장 지역별 분석

제6장 시장 전략

제7장 경쟁 정보

제8장 기업 개요

제9장 Global Insight Services 소개

KSA

The global GI Stool Testing Market is projected to grow from $377.4 million in 2025 to $763.4 million by 2035, at a compound annual growth rate (CAGR) of 7.3%. The GI Stool Testing Market is driven by the need for accurate detection of gastrointestinal infections, increasing use of molecular diagnostics, and demand for rapid identification of bacterial, viral, and parasitic pathogens. In February 2026, the CDC stated that serial stool examination remains the gold standard for diagnosing Strongyloides infection, highlighting the continued clinical importance of stool-based testing. In April 2025, CDC guidance also emphasized stool testing for parasitic diseases, including ova-and-parasite and antigen-based methods. Advances in multiplex PCR, antigen detection, and automated laboratory analysis are improving diagnostic speed and pathogen identification.

The Type segment of the GI Stool Testing Market includes Immunoassay Testing, Molecular Testing, Chromatography, Culture-Based Testing, Microscopy, and Others. Immunoassay Testing dominated the market in 2025 due to its widespread use, cost-effectiveness, rapid results, and established application in detecting gastrointestinal infections and biomarkers. Molecular Testing is expected to be the fastest-growing segment during the forecast period, driven by increasing adoption of PCR-based testing, higher sensitivity and specificity, multiplex pathogen detection, and growing demand for rapid and accurate diagnosis. Culture-Based Testing and Microscopy continue to support conventional diagnostic workflows, while chromatography and other advanced techniques are gaining attention for specialized stool analysis and biomarker detection.

Market Segmentation
TypeImmunoassay Testing, Molecular Testing, Chromatography, Culture-Based Testing, Microscopy, Others
ProductReagents, Kits, Instruments, Consumables, Others
ServicesLaboratory Testing Services, Point-of-Care Testing Services, Consultation Services, Others
TechnologyPCR, ELISA, Mass Spectrometry, Next-Generation Sequencing, Others
ApplicationInfectious Disease Detection, Cancer Screening, Inflammatory Conditions, Nutritional Deficiencies, Others
ProcessSample Collection, Sample Preparation, Analysis, Reporting, Others
End UserHospitals, Diagnostic Laboratories, Research Institutes, Home Care Settings, Others
ModeAutomated, Semi-Automated, Manual, Others

The End User segment of the GI Stool Testing Market includes Hospitals, Diagnostic Laboratories, Research Institutes, Home Care Settings, and Others. Hospitals dominated the market in 2025 due to high patient volumes, established diagnostic infrastructure, and increasing demand for gastrointestinal infection and disease diagnosis. Home Care Settings are expected to be the fastest-growing segment during the forecast period, supported by rising demand for convenient testing, at-home sample collection, remote healthcare services, and increased consumer interest in digestive health monitoring. Diagnostic Laboratories continue to play an important role due to specialized testing capabilities and outsourcing trends, while Research Institutes are expanding their use of stool testing for gastrointestinal disease research and microbiome studies.

Geographical Overview

North America was the leading region in the GI Stool Testing Market in 2025, supported by advanced healthcare infrastructure, well-established clinical laboratory networks, high healthcare spending, and widespread adoption of molecular and immunoassay-based diagnostic technologies. The region benefited from established colorectal cancer screening programs, strong awareness of gastrointestinal disorders, favorable access to diagnostic services, and increasing use of non-invasive stool-based testing. The United States represented the major contributor to regional demand, supported by extensive healthcare coverage and the presence of sophisticated diagnostic facilities.

Asia-Pacific is expected to be the fastest-growing region in the GI Stool Testing Market during the forecast period, driven by expanding healthcare infrastructure, rising healthcare expenditure, increasing awareness of gastrointestinal diseases, and growing adoption of advanced diagnostic technologies. Countries such as China, India, Japan, and South Korea are expected to contribute significantly to regional expansion as access to diagnostic services improves and demand for early and accurate disease detection increases. The rising prevalence of gastrointestinal infections and other digestive disorders, together with government initiatives to strengthen healthcare systems and diagnostic capabilities, is expected to further support the adoption of stool testing across the regio

Key Trends and Drivers

Shift Toward Multiplex Molecular and Microbiome-Based Stool Testing:

The GI Stool Testing Market is increasingly shifting from conventional culture, microscopy, and single-analyte assays toward multiplex PCR, syndromic molecular panels, and microbiome profiling. Multiplex PCR platforms can simultaneously identify bacterial, viral, and parasitic pathogens from a single stool specimen, reducing turnaround time and enabling more targeted treatment. At the same time, next-generation sequencing is expanding stool analysis beyond pathogen detection toward characterization of gut microbiota and dysbiosis, supporting personalized gastroenterology. The trend is also being reinforced by increasing clinical interest in rapid syndromic testing, particularly for patients with acute infectious diarrhea and complex gastrointestinal symptoms.

Rising Demand for Non-Invasive Detection of GI Disorders and Colorectal Cancer:

A major driver of the GI Stool Testing Market is the growing use of non-invasive stool-based diagnostics for colorectal cancer screening, inflammatory bowel disease, and gastrointestinal infections. FIT and other fecal occult-blood tests provide an accessible screening option for detecting gastrointestinal bleeding associated with colorectal abnormalities, while fecal calprotectin and lactoferrin help differentiate inflammatory bowel disease from functional disorders and can reduce unnecessary invasive investigations. Increasing colorectal cancer screening programs, growing incidence of GI disorders, and the need for earlier disease detection are expanding testing volumes. At the same time, multiplex molecular assays are increasing demand for rapid pathogen identification in acute gastroenteritis.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Immunoassay Testing
    • 4.1.2 Molecular Testing
    • 4.1.3 Chromatography
    • 4.1.4 Culture-Based Testing
    • 4.1.5 Microscopy
    • 4.1.6 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Reagents
    • 4.2.2 Kits
    • 4.2.3 Instruments
    • 4.2.4 Consumables
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Laboratory Testing Services
    • 4.3.2 Point-of-Care Testing Services
    • 4.3.3 Consultation Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 PCR
    • 4.4.2 ELISA
    • 4.4.3 Mass Spectrometry
    • 4.4.4 Next-Generation Sequencing
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Infectious Disease Detection
    • 4.5.2 Cancer Screening
    • 4.5.3 Inflammatory Conditions
    • 4.5.4 Nutritional Deficiencies
    • 4.5.5 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Research Institutes
    • 4.6.4 Home Care Settings
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Sample Collection
    • 4.7.2 Sample Preparation
    • 4.7.3 Analysis
    • 4.7.4 Reporting
    • 4.7.5 Others
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 Automated
    • 4.8.2 Semi-Automated
    • 4.8.3 Manual
    • 4.8.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Abbott Laboratories
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Bio-Rad Laboratories
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Qiagen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Roche Diagnostics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Danaher Corporation
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Becton Dickinson and Company
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Quest Diagnostics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Siemens Healthineers
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 PerkinElmer
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 bioMerieux
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Hologic
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 DiaSorin
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Luminex Corporation
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Genova Diagnostics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Promega Corporation
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Randox Laboratories
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Alere
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 EKF Diagnostics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Meridian Bioscience
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기